DANONE (BSN.DE) Stock Fundamental Analysis
Europe - FRA:BSN - FR0000120644 - Common Stock
72.14 EUR
-0.12 (-0.17%)
Overall BSN gets a fundamental rating of 4 out of 10. We evaluated BSN against 58 industry peers in the Food Products industry. There are concerns on the financial health of BSN while its profitability can be described as average. BSN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BSN had positive earnings in the past year.
BSN had a positive operating cash flow in the past year.
BSN had positive earnings in each of the past 5 years.
In the past 5 years BSN always reported a positive cash flow from operatings.
1.2 Ratios
BSN's Return On Assets of 4.20% is in line compared to the rest of the industry. BSN outperforms 58.62% of its industry peers.
BSN has a better Return On Equity (11.59%) than 62.07% of its industry peers.
BSN's Return On Invested Capital of 6.83% is fine compared to the rest of the industry. BSN outperforms 62.07% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BSN is in line with the industry average of 7.47%.
The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROIC | 6.83% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
BSN's Profit Margin of 6.72% is fine compared to the rest of the industry. BSN outperforms 72.41% of its industry peers.
In the last couple of years the Profit Margin of BSN has remained more or less at the same level.
The Operating Margin of BSN (13.25%) is better than 79.31% of its industry peers.
BSN's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 50.47%, BSN is doing good in the industry, outperforming 75.86% of the companies in the same industry.
In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
BSN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for BSN has been increased compared to 1 year ago.
The number of shares outstanding for BSN has been reduced compared to 5 years ago.
BSN has a better debt/assets ratio than last year.
2.2 Solvency
BSN has an Altman-Z score of 2.47. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
BSN has a Altman-Z score (2.47) which is in line with its industry peers.
The Debt to FCF ratio of BSN is 5.07, which is a neutral value as it means it would take BSN, 5.07 years of fcf income to pay off all of its debts.
BSN has a Debt to FCF ratio of 5.07. This is in the better half of the industry: BSN outperforms 67.24% of its industry peers.
BSN has a Debt/Equity ratio of 0.83. This is a neutral value indicating BSN is somewhat dependend on debt financing.
BSN has a Debt to Equity ratio of 0.83. This is in the lower half of the industry: BSN underperforms 68.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 2.47 |
ROIC/WACC1.08
WACC6.35%
2.3 Liquidity
A Current Ratio of 0.95 indicates that BSN may have some problems paying its short term obligations.
BSN's Current ratio of 0.95 is on the low side compared to the rest of the industry. BSN is outperformed by 75.86% of its industry peers.
BSN has a Quick Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.78, BSN is not doing good in the industry: 60.34% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.47% over the past year.
BSN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.17% yearly.
Looking at the last year, BSN shows a small growth in Revenue. The Revenue has grown by 0.54% in the last year.
Measured over the past years, BSN shows a small growth in Revenue. The Revenue has been growing by 1.60% on average per year.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
3.2 Future
The Earnings Per Share is expected to grow by 6.84% on average over the next years.
Based on estimates for the next years, BSN will show a small growth in Revenue. The Revenue will grow by 3.24% on average per year.
EPS Next Y7.65%
EPS Next 2Y6.85%
EPS Next 3Y7.31%
EPS Next 5Y6.84%
Revenue Next Year0.54%
Revenue Next 2Y1.69%
Revenue Next 3Y2.42%
Revenue Next 5Y3.24%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 19.29 indicates a rather expensive valuation of BSN.
BSN's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of BSN to the average of the S&P500 Index (27.76), we can say BSN is valued slightly cheaper.
A Price/Forward Earnings ratio of 17.41 indicates a rather expensive valuation of BSN.
The rest of the industry has a similar Price/Forward Earnings ratio as BSN.
The average S&P500 Price/Forward Earnings ratio is at 23.21. BSN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.29 | ||
| Fwd PE | 17.41 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as BSN.
BSN's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.13 | ||
| EV/EBITDA | 10.38 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BSN does not grow enough to justify the current Price/Earnings ratio.
BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.52
PEG (5Y)N/A
EPS Next 2Y6.85%
EPS Next 3Y7.31%
5. Dividend
5.1 Amount
BSN has a Yearly Dividend Yield of 2.91%.
Compared to an average industry Dividend Yield of 3.35, BSN pays a bit more dividend than its industry peers.
BSN's Dividend Yield is comparable with the S&P500 average which is at 2.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.91% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
74.99% of the earnings are spent on dividend by BSN. This is not a sustainable payout ratio.
The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP74.99%
EPS Next 2Y6.85%
EPS Next 3Y7.31%
FRA:BSN (10/7/2025, 7:00:00 PM)
72.14
-0.12 (-0.17%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners55.49%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap49.16B
Analysts74.84
Price Target78.66 (9.04%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.91% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.78%
PT rev (3m)2.29%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.47%
EPS NY rev (3m)-0.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.34%
Revenue NY rev (3m)-1.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.29 | ||
| Fwd PE | 17.41 | ||
| P/S | 1.8 | ||
| P/FCF | 17.13 | ||
| P/OCF | 12.78 | ||
| P/B | 3.1 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.38 |
EPS(TTM)3.74
EY5.18%
EPS(NY)4.14
Fwd EY5.74%
FCF(TTM)4.21
FCFY5.84%
OCF(TTM)5.64
OCFY7.82%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.52
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROCE | 12.02% | ||
| ROIC | 6.83% | ||
| ROICexc | 8.36% | ||
| ROICexgc | 50.58% | ||
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% | ||
| FCFM | 10.49% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexcg growth 3Y19.7%
ROICexcg growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 77.72% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 23.53 | ||
| Cash Conversion | 78.8% | ||
| Profit Quality | 156.01% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | 2.47 |
F-Score8
WACC6.35%
ROIC/WACC1.08
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y7.65%
EPS Next 2Y6.85%
EPS Next 3Y7.31%
EPS Next 5Y6.84%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.54%
Revenue Next 2Y1.69%
Revenue Next 3Y2.42%
Revenue Next 5Y3.24%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.38%
EBIT Next 3Y14.38%
EBIT Next 5Y10.86%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%